Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

51.00 +0.12 (+0.24%)
Streaming Delayed Price Updated: 3:59 PM EDT, May 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
36 37 Next >
News headline image
Stock Market Falls, S&P 500 Hits Bear Lows; Biogen, Nike, Micron Are Key Movers: Weekly Review ↗
The major indexes fell, with the S&P 500 breaking below bear market lows. 
Via Investor's Business Daily
News headline image
These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win ↗
 
Via Benzinga
News headline image
This Analyst Believes Biogen's Lecanemab Data Not 'Slam Dunk' For Complete CMS Approval ↗
 
Via Benzinga
News headline image
2 Sympathy Plays To Watch For In The Wake Of Biogen's Positive Alzheimer's Drug Data ↗
Biogen Inc. (NASDAQ: BIIB) and partner Eisai Co. Ltd. 
Via Benzinga
News headline image
FDA Approves Expanded Use Of Roche's Influenza Treatment ↗
 
Via Benzinga
News headline image
Kiniksa Inks Global License Agreement With Roche For Vixarelimab ↗
 
Via Benzinga
News headline image
FDA To Review Smaller Number Of Emergency Use Requests For COVID-19 Tests ↗
 
Via Benzinga
News headline image
COVID-19 Complacency Pushes Identification Of New Variants To Back Seat, WHO Warns ↗
The World Health Organization (WHO) warned that it struggles to identify and 
Via Benzinga
News headline image
Multiple Sclerosis Is A Crowded Space, But This Stock Is A Potential 6X Multi-bagger ↗
 
Via Benzinga
News headline image
Europe Approves First Bispecific Antibody From Roche For Two Eye Disorders ↗
 
Via Benzinga
News headline image
WHO Recommends Against Roche, GSK's COVID-19 Therapies Rendering Them Obsolete ↗
Due to the lack of effectiveness against omicron and the variants, World Health Organization (WHO) no longer recommends using two COVID-19 antibody therapies. 
Via Benzinga
News headline image
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin ↗
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why. 
Via Investor's Business Daily
News headline image
A Major October Catalyst Could Make This Eye Stock A Ten Bagger, Analyst Says ↗
Chardan initiated coverage on Outlook Therapeutics Inc (NASDAQ: OTLK) with a Buy rati 
Via Benzinga
News headline image
A Quick Look At The OTC Markets' Most-Active Securities In August - Here's What You Need to Know ↗
While July gave markets around the world a breather, August reestablished 2022’s choppy financial conditions. 
Via Benzinga
News headline image
Good Therapeutics Announces Acquisition of Conditionally Active PD-1-regulated IL-2 Program by Roche
From Good Therapeutics
Via Business Wire
News headline image
No More Free COVID-19 At-Home Tests, Federal Government Says ↗
CNBC reported that the federal government is set to suspend its offer of free at-home COVID-19 tests by Friday, September 2, without congressional au 
Via Benzinga
News headline image
Citi Is Bullish On This Large Pharma Stock On Upcoming Data Readout From Diabetes Candidate ↗
Citi has increased peak risk-adjusted Eli Lilly And Co's (NYSE: LLY) tirzepatide forecasts (diabetes/ obesity/NASH) to more than $25 billion (previously $15 billion, consensus of around $16 billion).  
Via Benzinga
News headline image
Week In Review: Everest Sells Trodelvy Rights Back To Gilead For $455 Million ↗
Shanghai Everest Medicines returned rights for Trodelvy to Immunomedics, now a subsidiary of Gilead Sciences, in an agreement worth up to $455 million ($280 million upfront). 
Via Talk Markets
News headline image
China-Based Jemincare Inks Prostate Cancer Drug Pact With Roche's Genentech ↗
 
Via Benzinga
News headline image
Roche's Polivy Combo Regime Under FDA Review For Type Of Blood Cancer ↗
 
Via Benzinga
News headline image
OTC Markets' Most Active Securities Sees A Shake-up In July ↗
July gave world markets a breather from 2022’s poor financial conditions. 
Via Benzinga
News headline image
FDA Accepts Supplemental Biologics License Application for Genentech's Polivy Combination for People With Previously Untreated Diffuse Large B-Cell Lymphoma
From Genentech
Via Business Wire
News headline image
Genentech Announces FDA Approval of Xofluza to Treat Influenza in Children Aged Five and Older
From Genentech
Via Business Wire
News headline image
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Amgen's Lumakras/Keytruda/Tecentriq Combo Data Flags Safety Concern ↗
 
Via Benzinga
News headline image
These 2 Under-The-Radar Stocks Traded More Than $1B Each Last Month ↗
The month of July saw $37.3 billion in trading volume for stocks that trade on the OTCQK and OTCQB. While some of the stocks that trade over-the-counter are considered penny stocks based on their share... 
Via Benzinga
News headline image
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Poseida Shares Rally As Roche Takes Next Big Step Into Allogeneic CAR-T Field ↗
 
Via Benzinga
News headline image
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Genentech’s Subcutaneous Formulation of Tecentriq Demonstrates Positive Phase III Results
From Genentech
Via Business Wire
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
36 37 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.